Fischer Medical

Why is Fischer Medical Ventures Ltd falling/rising?

As of 23-Jun, Fischer Medical Ventures Ltd's stock price is declining at 35.02, down -0.31%, with a total drop of -3.5% over the last three days. The stock is underperforming significantly, with a year-to-date decline of -16.42% and a staggering -58.78% over the past year, driven by poor financial results and negative market sentiment.

As of 23-Jun, Fischer Medical Ventures Ltd is experiencing a decline in its stock price, currently at 35.02, which reflects a change of -0.11 or -0.31%. The stock has been on a downward trend, having fallen consecutively for the last three days, resulting in a total decline of -3.5% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish sentiment among investors.<BR><BR>Despite a recent outperformance against its sector by 0.62%, the overall performance over the past month shows a significant decline of -4.37%, while the year-to-date performance reveals a substantial drop of -16.42%. Over the past year, the stock has dramatically underperformed, with a staggering return of -58.78%, compared to the market's negative return of -0.36%. <BR><BR>The company's financial results have also contributed to the negative sentiment. The latest quarterly results showed a significant decline in profit before tax and profit after tax, with decreases of -135.7% and -171.9%, respectively, compared to the previous four-quarter average. Furthermore, the company's valuation appears expensive, with a return on capital employed (ROCE) of only 8.6 and a high enterprise value to capital employed ratio of 5.1.<BR><BR>While there are positive indicators such as a strong ability to service debt and impressive long-term growth rates in net sales and operating profit, these have not been enough to offset the negative market perception and the company's poor recent performance. Additionally, the lack of investment from domestic mutual funds, which hold 0% of the company, suggests a lack of confidence in the stock's current valuation. Overall, these factors contribute to the ongoing decline in Fischer Medical Ventures Ltd's stock price.

Which are the latest news on Fischer Medical?

How big is Fischer Medical?

As of 10th June, Fischer Medical Ventures Ltd has a market capitalization of 2,058.00 Cr, with recent net sales of 308.58 Cr and a net profit of 31.04 Cr. Shareholder's funds are 337.52 Cr, and total assets amount to 456.98 Cr.

As of 10th June, Fischer Medical Ventures Ltd has a market capitalization of 2,058.00 Cr, categorizing it as a Small Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 308.58 Cr and a Net Profit of 31.04 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 337.52 Cr and Total Assets of 456.98 Cr.

Who are in the management team of Fischer Medical?

The management team of Fischer Medical includes Sejal Soni (Non Executive Director), Ashishkumar Dhakan (Independent Non Executive Director), Krishna Kumar Omprakash Dubey (Independent Director), Jeena Dineshchandra Suthar (Independent Women Director), and Dilip Suryakant Jha (Director & CFO), who collectively guide the company's governance and strategy.

The management team of Fischer Medical includes the following individuals:<BR><BR>1. Sejal Soni - Non Executive Director<BR>2. Ashishkumar Dhakan - Independent Non Executive Director<BR>3. Krishna Kumar Omprakash Dubey - Independent Director<BR>4. Jeena Dineshchandra Suthar - Independent Women Director<BR>5. Dilip Suryakant Jha - Director & CFO<BR><BR>These members contribute to the governance and strategic direction of the company.

Who are the peers of the Fischer Medical?

Fischer Medical's peers include GHCL, Tanfac Inds., Grauer & Weil, Chemplast Sanmar, Thirumalai Chem., J.G.Chemicals, I G Petrochems, Indo Borax & Ch., and TGV Sraac. Fischer Medical has Below Average management risk, Good capital structure, and a 1-year return of -61.28%, compared to peers with varying growth and return rates.

Peers: Fischer Medical's peers are GHCL, Tanfac Inds., Grauer & Weil, Chemplast Sanmar, Thirumalai Chem., J.G.Chemicals, I G Petrochems, Indo Borax & Ch., and TGV Sraac.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL and Chemplast Sanmar, while Average management risk is found at Tanfac Inds., Grauer & Weil, Thirumalai Chem., J.G.Chemicals, I G Petrochems, and TGV Sraac, and the rest. Below Average management risk is attributed to Fischer Medical. Growth is Excellent for Fischer Medical, while Good growth is noted at Tanfac Inds. and J.G.Chemicals, and the rest exhibit Below Average growth. Capital Structure is Excellent for GHCL, Tanfac Inds., Grauer & Weil, J.G.Chemicals, I G Petrochems, and Indo Borax & Ch., while Good capital structure is seen at Fischer Medical and TGV Sraac, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Indo Borax & Ch. at 77.84%, while the lowest is Chemplast Sanmar at -54.66%. Fischer Medical's own 1-year return is -61.28%, which is lower than both extremes. Additionally, GHCL, Chemplast Sanmar, Thirumalai Chem., and I G Petrochems all have negative six-month returns.

What does Fischer Medical do?

Fischer Medical Ventures Ltd specializes in trading MRI systems within the Commodity Chemicals industry and is classified as a Small Cap company. As of March 2026, it reported net sales of 98 Cr and a net profit of -7 Cr, with a market cap of INR 2,058 Cr.

Overview:<BR>Fischer Medical Ventures Ltd is emerging as a leading player in the trading of MRI systems within the Commodity Chemicals industry and operates in the Small Cap market-cap bracket.<BR><BR>History:<BR>Fischer Medical Ventures Ltd was incorporated in an unspecified year and has established itself as a significant player in the medical diagnostic and imaging technologies market. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 98 Cr (Quarterly Results - Mar 2026)<BR>Most recent Net Profit: -7 Cr (Quarterly Results - Mar 2026)<BR>Market-cap value: INR 2,058 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 67.00<BR>Industry P/E: 42<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.21<BR>Return on Equity: 8.08%<BR>Price to Book: 5.35<BR><BR>Contact Details:<BR>Address: 104 1st Fl Bhhind Poisar Depot, Raghuleela Mall Kandivali (W) Mumbai Maharashtra : 400067<BR>Email: fischerchemicltd@gmail.com<BR>Website: http://www.fischerchemic.in

Should I buy, sell or hold Fischer Medical Ventures Ltd?

When is the next results date for Fischer Medical Ventures Ltd?

The next results date for Fischer Medical Ventures Ltd is 29 May 2026.

The next results date for Fischer Medical Ventures Ltd is scheduled for 29 May 2026.

Are Fischer Medical Ventures Ltd latest results good or bad?

Fischer Medical Ventures Ltd's Q3 FY26 results are impressive, with a net profit of ₹19.23 crore and revenue growth of 760.43%. However, the stock has declined 68.90% from its 52-week high and has a high P/E ratio of 1,704, raising concerns about its valuation and market sentiment.

Fischer Medical Ventures Ltd's latest results for Q3 FY26 are quite impressive overall. The company reported a net profit of ₹19.23 crore, which represents a staggering year-on-year increase of 6,631.03%. Revenue for the same quarter reached ₹101.10 crore, marking a remarkable 760.43% growth compared to the previous year. Additionally, the operating margin improved to 21.34%, the highest on record for the company, and the profit after tax (PAT) margin increased to 19.02%, up 21.49 percentage points from the previous year.<BR><BR>However, despite these strong financial metrics, there are concerns regarding the stock's performance and valuation. The stock has seen a significant decline of 68.90% from its 52-week high, and currently trades at ₹38.63. Technical indicators suggest a bearish trend, and the company's valuation metrics, such as a P/E ratio of 1,704 times, raise questions about sustainability and market sentiment.<BR><BR>In summary, while the financial results indicate exceptional growth and profitability, the stock's performance and high valuation present challenges that investors should consider.

Is Fischer Medical technically bullish or bearish?

As of December 2, 2025, Fischer Medical's technical trend is mildly bearish, supported by bearish MACD and moving averages, mixed RSI signals, and a bearish outlook from Dow Theory.

As of 2 December 2025, the technical trend for Fischer Medical has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven by several key indicators. The MACD is bearish on the weekly and mildly bearish on the monthly, while the moving averages indicate a bearish trend on the daily. Bollinger Bands and KST also reflect a mildly bearish stance on both the weekly and monthly time frames. Although the RSI shows a bullish signal on the monthly, it has no signal on the weekly, indicating mixed momentum. The Dow Theory suggests a mildly bearish outlook on the weekly, with no trend on the monthly. Overall, the combination of these indicators supports a mildly bearish view.

How has been the historical performance of Fischer Medical?

Fischer Medical experienced significant growth from March 2024 to March 2025, with net sales rising to 110.70 Cr from 20.98 Cr, while total liabilities and assets increased to 456.98 Cr. However, profit after tax decreased slightly to 1.70 Cr, and cash flow from operating activities showed a negative trend.

Answer:<BR>The historical performance of Fischer Medical shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Fischer Medical's net sales surged to 110.70 Cr in March 2025 from 20.98 Cr in March 2024, indicating a substantial increase in total operating income, which also rose to 110.70 Cr from 20.98 Cr. The company's total expenditure, excluding depreciation, increased to 107.38 Cr from 19.12 Cr, primarily driven by a notable rise in the purchase of finished goods, which jumped to 95.28 Cr from 0.08 Cr. Operating profit (PBDIT) improved to 4.81 Cr from 2.36 Cr, while profit before tax increased to 2.71 Cr from 2.11 Cr. However, profit after tax slightly decreased to 1.70 Cr from 1.84 Cr. The consolidated net profit also fell to 1.47 Cr from 1.84 Cr, reflecting a decline in earnings per share to 0.03 from 0.34. On the balance sheet, total liabilities rose significantly to 456.98 Cr from 86.32 Cr, with total assets also increasing to 456.98 Cr from 86.32 Cr. Cash flow from operating activities showed a negative trend, with a cash outflow of 86.00 Cr in March 2025 compared to 7.00 Cr in March 2024, although cash flow from financing activities improved to 314.00 Cr from 37.00 Cr, resulting in a net cash inflow of 103.00 Cr by the end of March 2025.

Is Fischer Medical overvalued or undervalued?

As of June 1, 2024, Fischer Medical is considered very expensive with a PE ratio of 3780.80 and other high valuation metrics, despite impressive returns of 22.64% YTD and 1231.22% over three years, indicating it is overvalued compared to its peers.

As of 1 June 2024, Fischer Medical's valuation grade has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company's current valuation suggests it is overvalued, particularly highlighted by its staggering PE ratio of 3780.80, an EV to EBITDA of 1624.03, and a Price to Book Value of 18.09. These ratios are exceptionally high compared to its peers, such as Solar Industries with a PE of 123.77 and Godrej Industries, which is considered attractive with a PE of 46.63.<BR><BR>In comparison to its industry, Fischer Medical stands out as very expensive, with its valuation metrics far exceeding those of its competitors. The company's return performance has been impressive, with a YTD return of 22.64% compared to the Sensex's 5.66%, and a remarkable 3-year return of 1231.22% against 49.24% for the Sensex. However, despite these strong returns, the current valuation metrics indicate that Fischer Medical is overvalued in the market.

Who are the top shareholders of the Fischer Medical?

The top shareholder of Fischer Medical is Time Medical International Ventures Pte, holding 51.16%. Other significant shareholders include four Foreign Institutional Investors with 5.38%, and individual investors with 27.48%, while the highest public shareholder is Roopal Hitesh Kawa at 2.78%.

The top shareholders of Fischer Medical include Time Medical International Ventures Pte, which holds the largest stake at 51.16%. Additionally, there are four Foreign Institutional Investors (FIIs) that collectively own 5.38%. The highest public shareholder is Roopal Hitesh Kawa, with a holding of 2.78%. Individual investors also have a significant presence, holding 27.48% of the shares. Overall, the majority of the company's shares are held by promoters, and there are no pledged promoter holdings.

Has Fischer Medical declared dividend?

No Dividend History Available